Clinical trials: African Trypanosomiases
Human African Trypanosomiasis (HAT), Sleeping Sickness
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
This clinical trial is designed to prove the efficacy and safety of Fexinidazole as an oral treatment for human african trypanosomiasis in advanced stage. The Fexinidazole is compared to reference treatment NECT.
- Trial name
- NCT01685827
- Testing
- Fexinidazole, Nifurtimox, Eflornithine
- Where
- 10 sites in Central African Republic, Democratic Republic of the Congo and 1 more
- Volunteers
- 394 people
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
This study is aimed at assessing the tolerability and pharmacokinetic parameters of the fexinidazole in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, fexinidazole shows…
- Trial name
- NCT00982904
- Where
- France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African, Gambiense Trypanosomiasis
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
The goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Gambiense Trypanosomiasis, Sleeping Sickness
- Trial name
- OXA002 (NCT03087955)
- Testing
- Acoziborole
- Where
- 12 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 208 people
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis, Sleeping Sickness
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
This study determines the feasibility, diagnostic performance and cost for monitoring of eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of serological and molecular high throughput tests with and…
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- DiTECT-HAT-WP3 (NCT04099628)
- Testing
- Rapid diagnostic test (RDT); Serological and molecular tests on DBS
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 13,747 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Trypanosoma Brucei Rhodesiense; Infection
A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published…
- Trial name
- NCT06060600
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Paxmedica
Human African Trypanosomiasis
Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria
A prototype rapid diagnostic test (RDT) to simultaneously screen for gambiense human African trypanosomiasis (HAT) and diagnose P. falciparum malaria (the "HAT/malaria combo") has recently been developed.
- Trial name
- NCT03394976
- Testing
- No intervention
- Volunteers
- healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Trypanosomiasis, African
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from…
- Trial name
- NCT00146627
- Testing
- Eflornithine, Nifurtimox
- Where
- 4 sites in Democratic Republic of the Congo, Republic of the Congo
- Volunteers
- 280 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
To assess Drug drug interactions between Acoziborole and Dextromethorphan and Midazolam in healthy male volunteers.
- Trial name
- OXA-07 (NCT05947604)
- Testing
- Acoziborole, Midazolam, Dextromethorphan
- Where
- Malaysia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety.
- Trial name
- NECS (NCT00489658)
- Testing
- Eflornithine plus Nifurtimox combination therapy
- Where
- Uganda
- Volunteers
- 31 people
- Sponsor
- Epicentre
Human African Trypanosomiasis
Assessment of Recombinant HAT-RDT Specificity
Human African trypanosomiasis HAT, or sleeping sickness, is a tropical disease caused mainly by the parasite Trypanosoma brucei gambiense (gHAT).
- Trial name
- NCT05637632
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Trypanosomiasis, African
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00802594
- Testing
- DB289
- Where
- 2 sites in Angola, Republic of the Congo
- Volunteers
- 30 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Trypanosomiasis, African, Sleeping Sickness
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
The ultimate goal of this study is to show that fexinidazole offers an alternative over the existing treatments of Human African trypanosomiasis due to Trypanosoma brucei rhodesiense (r-HAT): melarsoprol in patients with stage 2…
- Conditions
- Trypanosomiasis, African, Sleeping Sickness, Trypanosoma Brucei Rhodesiense; Infection
- Trial name
- NCT03974178
- Testing
- Fexinidazole
- Where
- 2 sites in Malawi, Uganda
- Volunteers
- 45 people
- Sponsor
- Drugs for Neglected Diseases